BHC earnings analysis
What we found in BHC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Bausch Health Companies Inc. reported stronger-than-expected Q1 2026 results, with revenues of $2.52 billion, exceeding estimates by $279 million, and an adjusted diluted EPS of $0.78, surpassing expectations of $0.72. Despite a net loss due to a goodwill impairment charge, adjusted EPS demonstrated a 32% increase compared to the prior year, reflecting operational strength in key segments.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Significant Revenue Beat
- Actual revenue for Q1 2026 was $2.52 billion, beating estimates by approximately $279 million.
- Strong Adjusted EPS Performance
- Adjusted diluted EPS was reported at $0.78, exceeding estimates of $0.72 and up 32% from the same period last year.
- Operating Margins Improved
- Operating margin increased to 31.5%, up from 22.0% in the previous quarter (Q4 2025).
- Free Cash Flow Recovery
- Free cash flow improved significantly to $495 million compared to $190 million in Q4 2025.
- Refinancing Initiatives
- Successfully reduced near-term debt maturities by refinancing approximately $6.87 billion worth of obligations.
- Segment Growth in Salix
- Salix segment, driven by GI products, continues to be a strong revenue generator, contributing significantly to the overall revenue growth.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Goodwill Impairment Charge
- The company incurred a substantial net loss of $1,423 million due to a goodwill impairment charge affecting investor perception.
- Concentration Risk in Salix Segment
- Revenue from the Salix segment is highly concentrated, with approximately 85% derived from Xifaxan, exposing the company to risks associated with this product.
- Future Cash Flow Challenges
- Management highlighted ongoing challenges regarding cash flow generation and the need to access liquidity for upcoming debt maturities.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.78
- Operating margin
- 31.5%
- Segment
- Salix
- Segment
- International
- Segment
- Solta Medical
- Segment
- Diversified
- Segment
- Bausch + Lomb
What they said about what is next.
Management reaffirmed full-year guidance for revenue and adjusted EBITDA but did not provide specific numerical targets in the 10-Q.
The filing reads better than the one before it.
What came before.
- 10-K · February 19, 2026
- Bausch Health reported multi-year revenue growth to $10,266 million in 2025 (2024: $9,625M; 2023: $8,757M) while executing portfolio actions including the September 2025 acquisition of DURECT and maintaining a large…
- 10-Q · May 1, 2025
- Bausch Health reported Q1 2025 revenue of $2,259 million (up $106 million vs. Q1 2024's $2,153 million) with gross profit of $1,558 million (implying a ~69.0% gross margin). Operating income was $276 million (operating…
- 10-Q · October 31, 2024
- Bausch Health reported Q3 2024 revenue of $2,510 million, up from $2,238 million in Q3 2023, with gross margin of ~72.3% and operating income rising to $318 million (vs. $14 million a year ago). Despite improved…
- 10-Q · August 1, 2024
- Bausch Health reported Q2 revenue of $2,403 million, up $236 million (+10.9%) versus Q2 2023 and up $250 million (+11.6%) versus Q1 2024. GAAP diluted EPS for the quarter was $0.03; operating income was $389 million…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BHC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever